To learn more, they conducted a survey of roughly 2,000 people across four groups: people who are currently taking a GLP-1 drug for weight loss, people who have taken a GLP-1 drug in the past, people who are planning to take a GLP-1 drug, and people who havent and arent planning to take these drugs
Drugs Today (Barc) (2013) 49(9):53753
GLP-1 receptor agonists like semaglutide have demonstrated cardiovascular benefits beyond weight reduction, including modest blood pressure improvements in clinical populations
These characteristics make GLP-1 a promising therapeutic target, with several strategies developed to enhance its effects
Novo Nordisk Patient Assistance Program (PAP): Provides Wegovy, Ozempic, and Saxenda free to patients without insurance who meet income criteria
It empowers you to transition seamlessly from low introductory volumes up to advanced maintenance baselines without switching systems